Single-agent gemcitabine in the treatment of advanced biliary tract cancers: A phase II study

Japanese Journal of Clinical Oncology

Volumn 35, Issue 2, 2005, Pages 68-73

  Park, Jong Sung ^a   Oh, Sung Yong ^a   Kim, Sung Hyun ^a   Kwon, Hyuk Chan ^a   Kim, Jae Seok ^a   Kim, Hyo Jin ^a   Kim, Young Hoon ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

Biliary tract cancer; Cholangiocarcinoma; Gemcitabine

Indexed keywords

GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GALLBLADDER CARCINOMA; HUMAN; HUMAN CELL; LIVER TOXICITY; MALE; METASTASIS; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; BILIARY TRACT TUMOR; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; GALLBLADDER TUMOR; MIDDLE AGED; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BILIARY TRACT NEOPLASMS; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; SURVIVAL ANALYSIS; THROMBOCYTOPENIA;

EID: 15044354629     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyi021     Document Type: Article

References (30)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Shin HR, Lee CU, Park HJ, Seol SY, Chung JM, Choi HC, et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol 1996;25:933-40.
3. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N Engl J Med 1999;341:1368-78.
4. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 1984;54:965-9.
5. Harvey JH, Smith FP, Schein PS. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol 1984;2:1245-8.
6. Taal BG, Audisio RA, Bleiberg H, Blijham GH, Neijt JP, Veenhof CH, et al. Phase II trial of mitomycin C (MMC) in advanced gallbladder and biliary tree carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group Study. Ann Oncol 1993;4:607-9.
7. Sanz-Altamira PM, Ferrante K, Jenkins RL, Lewis WD, Huberman MS, Suart KE. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 1998;82:2321-5.
8. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
9. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, et al. Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001;12:183-6.
10. Lin MH, Chen JS, Chen HH, Su WC. A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy 2003;49:154-8.
11. Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D, et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 2004;22:193-8.
12. Gallardo JO, Rubio B, Fodor M, Orlandi L, Yanez M, Gamargo C, et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol 2001;12:1403-6.
13. Gebbia V, Giuliani F, Maiello E, Colucci G, Verderame F, Borsellino N, et al. Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 2001;19:4089-91.
14. Raderer M, Hejna MH, Valencak JB, Kornek GV, Weinlander GS, Bareck E, et al. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology 1999;56:177-80.
15. Fukuda H, Ohashi Y. A guideline for reporting results of statistical analysis in Japanese Jpn J Clin Oncol 1997;27:121-7.
16. Lund B, Kristjansen PE, Hansen HH. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 1993; 19:45-55.
17. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110-7.
18. O'Rourke TJ, Brown TD, Havlin K, Kuhn JG, Craig JB, Burris HA, et al. Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer 1994;30:417-8.
19. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-8.
20. Lee J, Park JO, Kim WS, Lee SI, Song SY, Lim do H, et al. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer. Oncology 2004;66:32-7.
21. Schneider BP, Ganjoo KN, Seitz DE, Picus J, Fata F, Stoner C, et al. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 2003;65:218-23.
22. Okusaka T. Chemotherapy for biliary tract cancer in Japan. Semin Oncol 2002;29:51-3.
23. Scheithauer W. Review of gemcitabine in biliary tract carcinoma. Semin Oncol 2002;29:40-5.
24. Kuhn R, Hribaschek A, Eichelmann K, Rudolph S, Fahlke J, Ridwelski K. Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas. Invest New Drugs 2002;20:351-6.
25. Doval DC, Sekhon JS, Gupta SK, Fuloria J, Shukla VK, Gupta S, et al. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. Br J Cancer 2004;90:1516-20.
26. Kornek GV, Schuell B, Laengle F, Gruenberger T, Penz M, Karall K, et al. Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomized phase II trial. Ann Oncol 2004;15:478-83.
27. Park JS, Lee CM, Lee SA, Jung CK, Kim SH, Kwon HC, et al. A 21-day schedule of gemcitabine and cisplatin administration in the treatment of advanced non small cell lung carcinoma: a phase II study. Cancer Res Treat 2004;1:62-7.
28. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003 15;21:3402-8.
29. Abratt RP, Sandler A, Crino L, Steward WP, Shepherd FA, Green MR, et al. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Semin Oncol 1998;25:35-43.
30. Shepherd FA, Abratt R, Crino L, Green M, Sandler A, Steward W, et al. The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer. Lung Cancer 2000;30:117-25.